Stage IV

Glecirasib demonstrates efficacy in KRASG12C-mutated NSCLC – ASCO

American Society of Clinical Oncology (ASCO) shared on X:

“Breaking news from the ASCO Plenary Series:

Glecirasib demonstrates encouraging efficacy and safety in KRASG12C-mutated Non- Small Cell Lung Cancer (NSCLC) in phase 2 trial from China.

ASCO Daily News has more.”

Glecirasib

Source: ASCO/X

American Society of Clinical Oncology ASCO ASCO Daily News cancer Glecirasib non small cell lung cancer NSCLC OncoDaily Oncology